Inherent resistance of colon cancer cells to cis-diamminedichloroplatinum(II) (CDDP) is partly attributed to reduced drug penetration through plasma membrane. Amphotericin B (AmB). a polyene antifungal antibiotic, has been shown to increase (unpublished results). The use of drugs that influence membrane permeability and which enhance transmembrane drug transport could be a useful method to circumvent the natural resistance of human colon cancer cells to cisplatin. In the present paper, we studied the effect of amphotericin B (AmB), a polyene antifungal antibiotic known to increase the permeability of the plasma membrane, on the accumulation and cytotoxicity of CDDP, and two derived compounds, in human colon cancer cells. Experiments were performed either in serum-free medium or in pure human serum in order to mimic a clinical situation.
Cisplatin (CDDP) is an important anti-cancer drug for the treatment of many solid tumours, but its efficiency is low in human colon cancer (Durant, 1980) . Natural or acquired resistance of cancer cells to CDDP could result from several mechanisms. including CDDP inactivation by glutathione or metallothionein. increased DNA repair (Timmer-Bosscha et al.. 1992) or reduced drug uptake (Richon et al., 1987; Andrews et al.. 1988; Bungo et al.. 1990 ). The mechanism of natural resistance of human colon cancer to CDDP and related compounds has not been clearly determined. We have previously observed a lower drug accumulation in several CDDP-resistant human colon cancer cell lines when compared with sensitive cancer cell lines originating from human oesophageal tumours (unpublished results) . The use of drugs that influence membrane permeability and which enhance transmembrane drug transport could be a useful method to circumvent the natural resistance of human colon cancer cells to cisplatin. In the present paper, we studied the effect of amphotericin B (AmB), a polyene antifungal antibiotic known to increase the permeability of the plasma membrane, on the accumulation and cytotoxicity of CDDP, and two derived compounds, in human colon cancer cells. Experiments were performed either in serum-free medium or in pure human serum in order to mimic a clinical situation. Cell survival after drug treatment was assayed by a modified colony-forming assay (Pelletier et al.. 1990 (Bradford, 1976) .
Materials and methods

Chemicals
Patients
Serum was collected from informed neutropenic patients presenting candidaemia treated in a haematological care unit. Blood was collected before and at the end of the first AmB infusion. AmB (1 mg kg-') in the form of Fungizone was dissolved in distiled water, diluted in 50 ml of a lipid solution (Intralipid) and perfused over 1 h.
Results
Deleterious influence of serwn on the AmB-induced potentiation of CDDP In order to determine if the AmB-CDDP combination could be clinically useful, we performed the next HT 29 cell treatment in human serum. Serum provoked a significant but limited diminution of the cytotoxicity of CDDP used alone (Figure 4) . The IC54 was increased from 4 iLg ml-' in the presence of protein-free Ham medium to 7.5 Lg ml1' when incubation was performed in pure serum. Each point is the mean of four determinations. s.d. was inferior to 5% of the values.
Potentiation of CDDP accumulation and cytotoxicity by AmB determined in serum-free medium
The effect of AmB on CDDP, L-OHP and Carbo-P cellular accumulation was first studied in HT 29 cells in the presence of serum-free Ham FIO medium (Figure 1 ). Cellular platinum content was strongly increased when HT 29 cells were incubated with CDDP in the presence AmB. AmBinduced enhancement of platinum cellular accumulation was less pronounced for Carbo-P and L-OHP. Figure 2 shows that 5-20 gml-' AmB increased the cytotoxic effect of CDDP on HT 29 cells. AmB up to 20 Lg ml-' had no toxicity by itself. The IC5( of CDDP changed from 4;Lgml-' when the drug was used alone to 0.6, 0.5 or 0.3 iLg ml-' when it was associated with 5, 10 or 20Lgml-' AmB respectively. L-OHP (IC5, 4p±gml-') was slightly more cytotoxic than Carbo-P (ICm0 9 Lgml-'), but the efficacy of both drugs was not modified by Amb ( Figure  3 ). that cell incubation with serum completely abolished the AmB-induced potentiation of CDDP. In accordance with this. we observed that serum abolished the AmB-induced increase of the cellular platinum content that was evident in serum-free medium ( Figure 6 ). Cellular platinum content was measured after a CDDP incubation of HT 29 cells in serum obtained from AmBtreated patients (Figure 7) . Platinum content was increased only 1.6-fold in the presence of a patient serum that contained 7.36 pg ml-' Amb but was not modified in presence of serum from any of three other patients in whom AmB concentration was 5.23. 4.89 and 4.29 pg ml-'.
Effect of serum dilution on the AmB-induced potentiation of CDDP As the potentiation of the CDDP accumulation and cytotoxicity by AmB was strongly hampered in presence of human serum, we investigated if dilution of the serum by an osmotic fluid could restore in vitro the positive AmB effect on the platinum cellular accumulation (Figure 8) CDDP in the presence (0) (Valeriote et al.. 1984 : Masuda et al.. 1991 Monrkage et al.. 1991 Monrkage et al.. . 1993 . AmB is a macrolide polyene antifungal antibiotic (MW 924) that binds irreversibly to the sterol components in the cell membrane. AmB insertion in the plasma membrane leads to the formation of 4-10 A pores and provokes a leak of electrolytes and metabolites and increases the cellular permeability to various drugs (Binet & Boland, 1988 : Brajtburg et al.. 1990a ). The greater cytotoxicity of AmB in fungal cells compared with mammalian cells is attributed to its greater affinity for ergosterol than for cholesterol (Kotler-Brajtburg et al.. 1974 : Cheron et al.. 1988 ). In concordance with Morikage et al. (1993) . we observed that AmB and CDDP must be given simultaneously in order to obtain the maximal potentiating effect (data not shown). Perturbation of the plasma membrane structure induced by AmB appears as transient. even if the antifungal agent persists for a long time in the cell membrane (Collette et al.. 1989) . As AmB induced only a reduced penetration of Carbo-P and L-OHP compared with CDDP. it can be speculated that all the platinumderived anti-cancer drugs do not share the same pathway to cross the plasma membrane.
HT 29 human colon cancer cells are extremely resistant to CDDP and its derivatives. About 10-20% of cells are able to survive after a 3 h treatment with drugs at 50 g ml'. This serum level is far above the clinically achievable concentrations. which do not exceed 2-4 jg ml-' for a few minutes after an intravenous infusion. As AmB given at non-toxic concentration dramatically decreased this high level of resistance by increasing the intracellular platinum content. we believe that the natural resistance of colon cancer cells to CDDP is more probably the result of a reduced transmembrane penetration than of an enhanced intracellular detoxification. The necessity of a large increase in platinum cellular content to produce a clear enhancement of CDDP cytotoxicity in cancer cells is probably related to the very low fraction (about 1%) of the DNA-bound platinum. whereas most of the drug is complexed to cytosolic and nuclear proteins (Pinto & Lippard. 1985) .
The range of AmB concentration which is required to produce an in vitro potentiation of CDDP is above the AmB level reached in patient serum after the administration of conventional doses of AmB. Binschadler et al. (1969) reported that AmB serum concentrations ranged only from 0.5 to 2.5 gml-' after a 4h infusion of 0.4-1.5 mg kg-' AmB diluted in 5% dextrose. Higher serum concentrations of AmB (up to 6 iLg ml-') were measured when AmB was administered as a liposomal formulation (Brajtburg et al.. 1990b) . In the present work. AmB was administered to the patients after dilution in a lipid solution (Intralipid). This method permitted. like the liposomal formulation. the use of a higher daily dose (up to 2 mg kg-' day-'). a reduced general and renal toxicity. a shorter duration of infusion over 1 h and a conserved clinical efficacy of AmB on fungal infections (Caillot et al., 1993) . Despite the high AmB concentration obtained after the infusion of AmB-Intralipid, CDDP accumulation was not or only slightly increased when HT 29 cells were incubated with CDDP in the presence of the serum from AmB-treated patients. The maximum increase of CDDP accumulation (1.6-fold for a 7.36 jug ml-' AmB concentration) was not sufficient to increase significantly the CDDP cytotoxicity.
A major observation in this work was that the potentiating effect of AmB on the CDDP accumulation and cytotoxicity of HT 29 cells was dramatically hampered when the cell incubation was performed in pure human serum instead of serum-free medium. AmB is known to highly bind serum protein. mainly lipoproteins (Block et al.. 1974) . At a concentration of 1.6 gg ml-', the mean binding of AmB to serum proteins is 95%. Inactivation of the membrane effect of AmB in presence of serum proteins could explain the disappointing results of several clinical trials. AmB has been associated with lomustine, doxorubicin and cyclophosphamide and other antineoplastic drugs without evident proof of clinical efficacy (Chabot et al., 1989; Presant et al.. 1980 Presant et al.. . 1987 . Despite the well-known potentiation of CDDP by AmB in vitro, no conclusive results have been published on the efficacy and toxicity of the AmB-CDDP association in patients with CDDP-refractory tumours.
As haemodilution is a commonly used technique in anaesthesiology or in emergency care (Boldt et al., 1990) , we tested if dilution of human serum in a non-protein osmotic solution could restore the AmB-induced potentiation of CDDP. Unfortunately. we observed that even a low percentage of serum (25%) in the replacement solution strongly hampered the positive effect of AmB on the CDDP penetration in vitro. As a complete replacement of blood by Lomol is unrealisable in patients. further investigations using the haemodilution technique to circumvent CDDP resistance by AmB are not warranted Considering our negative data. we do not presently advocate clinical trials with the AmB-CDDP combination in CDDP-refractory carcinomas, such as colon tumours. Moreover. combination of AmB and CDDP could have severe drawbacks in vivo owing to the overlapping renal toxicity of both drugs. We propose to seek other drugs which share the same permeabilising activity as AmB on plasma membrane but which display a reduced binding to serum proteins.
